Research Article
Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients
Table 1
Baseline patients characteristic.
| | Characteristic | Value |
| | Age (Mean ± SD, range) | 45.74 + 15.98 (18–81) |
| | Male, (%) | 36 (52.2%) |
| | WBC × 109/L (Mean ± SD, range) | 73.19 ± 72.95 (0.6–300) |
| | HB g/L (Mean ± SD, range) | 8.01 ± 1.95 (3.8–14.2) |
| | Plt × 109/L (Mean ± SD, range) | 54.27 ± 50.18 (3–320) |
| | BM blast% (Mean ± SD, range) | 69.52 ± 22.58 (25–100) |
| | FAB subtypes, (%) | | M0 | 1 (1.4%) | | M1 | 7 (10.1%) | | M2 | 27 (39.1%) | | M4 | 13 (18.8%) | | M5 | 19 (27.5%) | | M6 | 2 (2.9%) |
| | FLT3.ITD mutation status, (%) | | Unmutated | 40 (58%) | | Mutated | 19 (27.5%) | | Missing data | 10 (14.5%) |
| | NPM1 mutation status, (%) | | Unmutated | 39 (56.5%) | | Mutated | 20 (29%) | | Missing data | 10 (14.5%) |
| | Risk, (%) | | Favorable risk | 17 (24.6%) | | Intermediate risk | 23 (33.3%) | | Poor risk | 19 (27.5%) | | Missing data | 10 (14.5%) |
| | Response (%) | | Achieve 1st complete response (CR) | 57 (82.6%) |
| | Relapse/refractory disease, (%) | | Relapse/refractory | 38 (55.1%) |
|
|
